Navigation Links
Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption
Date:4/27/2009

LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- Pomegranate juice may slow the progression of post-treatment prostate cancer recurrence, according to new long-term research results being presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA). Researchers found that men who have undergone treatment for localized prostate cancer could benefit from drinking pomegranate juice.

The two-stage clinical trial followed a total of 48 participants over six years. Eligible participants had a rising PSA after surgery or radiotherapy, a PSA greater than 0.2 ng/ml and less than 5 ng/ml and a Gleason score of 7 or less. These patients were treated by drinking eight ounces of pomegranate juice daily. Currently, in the sixth year of treatment, active patients who remain on the study have a median total follow-up of 56 months. These participants continue to experience a significant increase in PSA doubling time following treatment, from a mean of 15.4 months at baseline to 60 months post-treatment, with a median PSA slope decrease of 60 percent, 0.06 to 0.024.

Researchers compared active patients, who remain on the study, with non-active patients, who no longer remain on the study. Though these two groups demonstrated similar mean PSA doubling times at baseline, both the PSA doubling time prolongation and the decline in median PSA slope were greater in active patients when compared to non-active patients.

"This study suggests that pomegranate juice may effectively slow the progression of prostate cancer after unsuccessful treatment," said Christopher Amling, MD, an AUA spokesman. "This finding and other ongoing research might one day reveal that pomegranate juice is an effective prostate cancer preventative agent as well."

Parts of this ongoing study suggest that some patients may be more sensitive to the effects of pomegranate juice on PSA doubling time. Phase three of this study is currently underway to further evaluate the benefits of pomegranate juice in a placebo-controlled manner.

NOTE TO REPORTERS: Experts are available to discuss these studies outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at the number below or e-mail Lacey Dean at LDean@AUAnet.org.

Pantuck, A; Zomorodian, N; Rettig, M; Aronson, W; Heber, D; Belldegrun, A. Long term follow up of phase 2 study of pomegranate juice for men with prostate cancer shows durable prolongation of PSA doubling time. J Urol, suppl. 2009: 181, 4, abstract 826.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.

    MEDIA CONTACTS:  AUA Media Relations (on-site):  312-528-8253
    Wendy Isett (cell):  410-977-4770


'/>"/>
SOURCE American Urological Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. First Swiss Patients Treated with the Percutaneous MitraClip(R) System
2. New Proton Therapy Equipment Enables More Tumors to be Treated
3. New Research Suggests Platelet Stickiness May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease
4. Cardiac Disease in Women Remains Untreated for Decades
5. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
6. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
7. Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
8. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
9. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
10. American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression
11. First European Patients Treated With the Percutaneous MitraClip(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Texas , Dec. 9, 2016  RxWiki Inc., ... apps, and digital marketing strategies of thousands of pharmacies ... it won Austin Inno,s "50 on Fire" ... "We,re pleased to accept the award as ... Loughlin , Chief Executive Officer at RxWiki. "Our platform ...
(Date:12/9/2016)... Dec. 9, 2016  Forge Therapeutics, Inc. today ... Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance ... the treatment of bacterial infections including those caused ... as an attractive antibacterial target for more than ... suitable chemical starting points has hampered its progress. ...
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... ... such as reducing loss of blood during surgeries, lowering the ... surgeries, and decreasing risks of SSIs. The patient warming systems ... and intravascular warming systems.These benefits in turn reduce the stay ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio , ... first national #QuackGivesBack campaign which supported local breast cancer organizations during National Breast ... Quack Gives Back initiative, and we’re very pleased with the participation in ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
(Date:12/8/2016)... , ... December 08, 2016 , ... David J. ... global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, ... the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology ...
Breaking Medicine News(10 mins):